CASE REPORT article

Front. Oncol.

Sec. Genitourinary Oncology

Volume 15 - 2025 | doi: 10.3389/fonc.2025.1631155

Complete Response with Combination Oncolytic Virus Immunotherapy in a Patient with Stage IV Renal Cell Carcinoma-a Promising Innovative Approach: Case Report

Provisionally accepted
Benjamin GesundheitBenjamin Gesundheit1*Chaim BraunsChaim Brauns1Thomas VoglThomas Vogl2Alexander MuckenhuberAlexander Muckenhuber3Christine WeissleinChristine Weisslein1Harald SchmollHarald Schmoll1Ronald EllisRonald Ellis1Yehudit PosenYehudit Posen1Jayadeepa SrinivasJayadeepa Srinivas1
  • 1RapoYerape Ltd., Jerusalem, Israel
  • 2Frankfurt University Hospital, Frankfurt, Germany
  • 3Technical University of Munich, Munich, Germany

The final, formatted version of the article will be published soon.

Select one of your emails

You have multiple emails registered with Frontiers:

Notify me on publication

Please enter your email address:

If you already have an account, please login

You don't have a Frontiers account ? You can register here

Metastatic renal cell carcinoma Stage-IV (RCC-IV) remains a therapeutic challenge, with an overall 5-year survival rate of 12%. While conventional chemotherapy and radiotherapy show relatively low efficacy as to morbidity and mortality, promising clinical results with fewer adverse events (AEs) are achieved with innovative immunotherapies. Oncolytic virus (OV) immunotherapy has been used with remarkable therapeutic effects in many solid cancers, including refractory and end-stage tumors, with intra-tumoral injection (IT-OV) suggested to improve its efficacy and tolerability. We report the clinical course of a patient with RCC-IV who was treated for 3 years with multiple IT injections of various OVs and another immunotherapeutic. Complete response, as documented by periodic radiological surveillance and biopsies, was achieved without any serious side effects, hospital admission or surgery during the entire treatment course. This is the first known report documenting complete remission of RCC-IV mediated by IT-OV. We discuss the rationale and potential of IT-OV as an innovative approach for RCC-IV treatment.

Keywords: Renal cell carcinoma, Oncolytic Virotherapy, Intratumoral, Immunotherapy, abscopal effect

Received: 19 May 2025; Accepted: 18 Jun 2025.

Copyright: © 2025 Gesundheit, Brauns, Vogl, Muckenhuber, Weisslein, Schmoll, Ellis, Posen and Srinivas. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Benjamin Gesundheit, RapoYerape Ltd., Jerusalem, Israel

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Supplementary Material